NextPlat (NXPL) Total Current Liabilities (2010 - 2026)
NextPlat's (NXPL) quarterly Total Current Liabilities came in at $11.0 million in Q2 2026, up 76.9% year-over-year from $6.2 million in Q2 2025, and up 20.84% quarter-over-quarter from $9.1 million in Q1 2026.
Analysis
NextPlat (NXPL) Total Current Liabilities (2010 - 2026) Analysis & Trends
NextPlat (NXPL) has reported Total Current Liabilities for 15 consecutive years, with $11.0 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Total Current Liabilities rose 76.9% year-over-year to $11.0 million in Q2 2026; TTM through Jun 2026 was $11.0 million, a 76.9% increase from a year earlier, with the FY2025 full-year figure at $9.1 million, up 11.16% from the prior year.
- Total Current Liabilities was $11.0 million for Q2 2026 at NextPlat, up from $9.1 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $16.0 million in Q1 2024 and troughed at $1.5 million in Q3 2022.
- A 5-year average of $7.6 million and a median of $8.3 million in 2024 frame the typical range for Total Current Liabilities.
- Across the five-year window, Total Current Liabilities surged 901.31% in 2023 and slumped 51.31% in 2025, its largest moves.
- Over 5 years, Total Current Liabilities stood at $2.1 million in 2022, then soared by 590.45% to $14.2 million in 2023, then plunged by 42.33% to $8.2 million in 2024, then gained by 11.16% to $9.1 million in 2025, then rose by 20.34% to $11.0 million in 2026.
- The last three Total Current Liabilities figures came in at $11.0 million (Q2 2026), $9.1 million (Q1 2026), and $9.1 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn | 15.65 Bn |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn | 6.35 Bn |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn | 1.66 Bn |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn | 883.19 Mn |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn | 4.54 Bn |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn | 283.66 Mn |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn | 331.18 Mn |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn | 263.21 Mn |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn | 12.39 Mn |
| 10 | NextPlat | 24.77 Mn | 12.93 Mn | 4.69 Mn | 10.98 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 10.98 Mn |
| Mar 31, 2026 | 9.09 Mn |
| Dec 31, 2025 | 9.13 Mn |
| Sep 30, 2025 | 7.36 Mn |
| Jun 30, 2025 | 6.21 Mn |
| Mar 31, 2025 | 8.42 Mn |
| Dec 31, 2024 | 8.21 Mn |
| Sep 30, 2024 | 9.67 Mn |
| Jun 30, 2024 | 12.75 Mn |
| Mar 31, 2024 | 15.95 Mn |
| Dec 31, 2023 | 14.24 Mn |
| Sep 30, 2023 | 14.69 Mn |
| Jun 30, 2023 | 1.79 Mn |
| Mar 31, 2023 | 2.33 Mn |
| Dec 31, 2022 | 2.06 Mn |
| Sep 30, 2022 | 1.47 Mn |
| Jun 30, 2022 | 1.51 Mn |
| Mar 31, 2022 | 1.71 Mn |
| Dec 31, 2021 | 2.78 Mn |
| Sep 30, 2021 | 1.24 Mn |